Human Papillomavirus (HPV)-vaccine produced in bacterial cells
Cervical cancer is one of the most common cancers in women worldwide and the incidence correlates with HPV (human Papillomavirus) infection. The two commercially available vaccines against HPV only protect against new infections (prophylactic vaccination), whereas existing infections are not cleared. The current technology provides a vaccine with the capability to function both as a prophylactic and a therapeutic vaccine. Moreover, it can be produced in bacterial cells, which makes production very cost-effective.
Further Information: PDF
Deutsches Krebsforschungszentrum DKFZ
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Properties of new materials for microchips
… can now be measured well. Reseachers of Delft University of Technology demonstrated measuring performance properties of ultrathin silicon membranes. Making ever smaller and more powerful chips requires new ultrathin…
Floating solar’s potential
… to support sustainable development by addressing climate, water, and energy goals holistically. A new study published this week in Nature Energy raises the potential for floating solar photovoltaics (FPV)…
Skyrmions move at record speeds
… a step towards the computing of the future. An international research team led by scientists from the CNRS1 has discovered that the magnetic nanobubbles2 known as skyrmions can be…